Has Jeffrey Kramer, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,608 in general payments to Jeffrey Kramer, MD across 82 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jeffrey Kramer, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jeffrey Kramer, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jeffrey Kramer, MD

Neurology · Chicago, ILNPI 1124056486

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (59.2%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Biogen at 45.7% of the total. Reporting peaked in 2019 at $2,151 and has fallen 95.7% since, to $92 in 2021.

$2,608in general payments, 2019–2025

Across 82 payments — averaging $31.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Biogen$1K
Lilly USA, LLC$263
Sunovion Pharmaceuticals Inc.$168
AbbVie$135
Novartis$131
Genentech USA, Inc.$94
plus $626 from 17 others

What the payments were for

Consulting fees$1,05040%
Speaking & faculty fees$130%
Food & beverage$1,54559%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Biogen	9	$1,191
Lilly USA, LLC	11	$263
Sunovion Pharmaceuticals Inc.	8	$168
AbbVie(2 entities)	9	$135
Novartis	7	$131
Genentech USA, Inc.	6	$94
AstraZeneca	3	$78
MDD US Operations, LLC	4	$71
Sanofi	3	$69
UCB, Inc.	2	$61
Adamas Pharmaceuticals, Inc.	3	$45
EMD Serono, Inc.	2	$43
Acadia Pharmaceuticals Inc	2	$38
Teva Pharmaceuticals USA, Inc.	2	$37
E.r. Squibb & Sons, L.L.C.	2	$32
Amgen	2	$28
Boston Scientific	1	$24
Bristol Myers Squibb	1	$23
Jazz Pharmaceuticals Inc.	1	$19
Amneal Pharmaceuticals LLC	1	$17
Chiesi USA, Inc.	1	$17
Acorda Therapeutics, Inc	1	$13
Merck	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

TYSABRI$1,050

How this compares

$2,608 in reported general payments places this provider in the 65th percentile of 790 neurology providers in Illinois.

See all neurology providers in Illinois →

Medicare billing

Part B allowed, 2024

$60,028

Medicare patients

244

Services billed

625

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Nurtec OdtRimegepant Sulfate	15	$24,169
Aimovig AutoinjectorErenumab-Aooe	12	$8,167
Levetiracetam	36	$2,159
Memantine Hcl	54	$1,799
Carbidopa-LevodopaCarbidopa/Levodopa	64	$1,795
Gabapentin	68	$1,119
Donepezil Hcl	83	$822
Primidone	19	$763
Escitalopram Oxalate	43	$673
Clonazepam	46	$385
Lamotrigine	15	$336
Amitriptyline Hcl	16	$313
Duloxetine Hcl	18	$304
Atorvastatin Calcium	21	$172
Sertraline Hcl	17	$157

Paid to pharmacies, not to this prescriber.

Other neurology in Chicago

Augusto MiravalleChicago$1.4M
Adil JavedChicago$584K
Danny BegaChicago$442K
Michael SmithChicago$382K
Dusan StefoskiChicago$294K
Veronica CiprianiChicago$289K
Thomas ShoemakerChicago$278K
Bruce CohenChicago$276K
Margaret ParkChicago$245K
Leonard Verhagen MetmanChicago$245K

See the full list for Illinois →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →